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METHODS AND COMPOSITIONS FOR THE
TREATMENT OF PSORIASIS

a symmetric polyarthritis; arthritis mutilans; and sacroiliitis

REFERENCE TO RELATED APPLICATIONS

sue is associated With a different histological and antigenic
pro?le than normal skin. Dabelsteen et al. used a panel of

and spondylitis.
The in?ammation and hyperproliferation of psoriatic tis

This application claims the priority bene?t of US. Pro
visional Patent Application No. 60/065,774, ?led Nov. 17,

anti-carbohydrate monoclonal antibodies to compare psori
atic tissue With the surrounding dermis. The glycosylation
pattern in psoriatic epithelium is changed in tWo Ways: some

1997. The priority application is hereby incorporated herein
by reference in its entirety.
STATEMENT OF RIGHTS TO INVENTIONS
MADE UNDER FEDERALLY SPONSORED
RESEARCH

This invention Was made in part during Work supported
by a grant from the United States Public Health Service

carbohydrates are expressed at an earlier stage of cell
10

maturation. In addition, certain biosynthetic precursor anti
gens not expressed in normal skin Were found in psoriatic
skin.
Paller et al. (1989) investigated the distribution of gan

15

(CA72018). The government has certain rights in the inven
tion.

glioside GM3 using an antibody designated 8G9D8. At the
electron microscope level, antibody deposition Was seen in
the corneocyte envelope. Disposition Was signi?cantly
decreased or absent in disorders of excessive keratinocyte

proliferation, including squamous cell carcinomas, congeni
tal ichthysiform erythrodermas, prokeratosis, and psoriasis.

BACKGROUND

Psoriasis is a chronic condition that affects as much as 20 In a subsequent study, Paller et al. (1993) found that When

2.6% of the population of the developed World. A recent
survey reported by the National Psoriasis Foundation esti
mates that 6.4 million people suffers from psoriasis, of

GM3 Was added to keratinocytes from normal foreskin,

lesional skin from patients With psoriasis or ichthyosis, and
to cutaneous squamous carcinoma lines, it inhibited groWth

Which about 500,000 is rated as severe. The annual patient

cost for treating psoriasis is currently estimated at $1.6 to
$3.2 billion. Every year, about 400 people are granted

in a dose-dependent manner at concentrations of 10—100
25

sensitive. The gangliosides GD3, 9-O-acetyl-GD2, and
GD1b also inhibited keratinocyte proliferation. Ganglio

disability by the Social Security Administration, and another
400 people die from psoriasis-related causes.
Characteristics of Psoriasis
It is not knoWn What causes psoriasis, although there is
evidence of a genetic predisposition and an autoimmune

sides GM1 and GD1a, and sialic acid had little effect. The
30

Concharenko et al. studied ganglioside expression on the

erythrocytes and serum of healthy subjects, and patients
With psoriasis. During phases of exacerbation, a marked
35

decrease Was observed in the content of GM2 and GM3
fractions of the red cells, and GD1a decreased in serum. The
presence of a neW monosialoganglioside fraction Was noted
during exacerbation, both in serum and on red cells. The

40

psoriasis Was almost normal.
Heidenheim et al. describe a monoclonal antibody desig
nated UM4D4 Which recogniZes the cell surface marker
CDW60. This marker is present on a subset of normal T cells,

factors such as stress and diet.
In normal skin, the time for a cell to move from the basal

layer through the granular layer is 4—5 Weeks. In psoriatic
lesions, the time is decreased 7—10 fold because of a
shortened cell cycle time, an increase in the absolute number
of cells capable of proliferating, and an increased rate of
division. T cell mediated immune responses appear to be

responsible for the in?ammation and hyperproliferation of
keratinocytes. Neutrophils are found in psoriatic lesions,

ganglioside spectrum of patients in clinical remission of

melanocytes, malignant melanoma cells, and hyperprolif
45

erative psoriatic keratinocytes. CDW60 antibodies bind to
the acetylated form of GD3. 74% of basal cell carcinomas
express CDW60, Whereas CDW50 expression in normal skin
is con?ned to melanocytes and a feW scattered keratinocytes
at the basal cell layer. Skov et al. recently reported that in

50

psoriatic skin, basal and suprabasal keratinocytes express

associated With increased levels of plasminogen activator.
Psoriatic ?broblasts have increased levels of enZymes

involved in collagen synthesis, secondary to expansion of
the papillary dermis. Psoriatic plaques comprise HLA-DR
positive keratinocytes and Langerhans cells, and activated T
cells expressing elevated levels of IL-2 receptors.
The typical lesion of psoriasis is a Well-demarcated

CDW60. Cloned T cell lines obtained from lesional skin
upon initiation Were found to release a cocktail of soluble

erythematous plaque, covered by thick, silvery scales. Pso
riasis can become so extensive as to cause exfoliative

erythroderma, in Which the entire epidermal surface is in a
state of hyperproliferation. Gluttate psoriasis is a form of the

55

60

threatening episode of fever, chills, leukocytosis,
hypoalbuminemia, and hypocalcemia, demanding
immediate, vigorous therapy. Previously stable plaque-type
psoriasis can be acutely exacerbated by viral infections,
particularly HIV. Psoriasis is also associated With ?ve dif

ferent forms of psoriatic arthritis, including distal interpha
rangeal involvement; an asymmetric, oligoarticular pattern;

factors including IL-4 and IL-13, that up-regulated CDW60
expression on cultured normal keratinocytes.
Currently Available Treatments for Psoriasis

Classical treatments of psoriasis include calciptriene (a
vitamin D3 derivative), topical coal tar preparations, sys

disease folloWing streptococcal pharyngitis, With Widely
distributed characteristic 1—3 cm lesions. Pustular psoriasis
is characteriZed by numerous sterile pustules of 2—5 mm in
diameter, and may lead to an acute, explosive, life

authors concluded that preferential activation of sialyltrans
ferase II may be involved in control of keratinocyte groWth,
but not differentiation.

etiology. Onset may be triggered by systemic infections such
as strep throat, skin injury, vaccinations, and certain oral
medications such as steroids. Subsequently, the immune
system is thought to induce in?ammation and excessive skin
cell reproduction, Which can be exacerbated by additional

pM. Con?uent undifferentiated keratinocytes Were least

65

temic antimitotic agents such as methotrexate, and retinoids,
particularly etretinate. Extensive psoriasis can be treated by
photosensitiZation With oral 8-methoxypsoralen, folloWed
by ultraviolet A. Corticosteroids are given for psoriatic
arthritis and acute attacks of pustular psoriasis. More
recently, cyclosporin A has been tested in clinical trials at
doses of 3—7 mg/kg With promising results, but associated
With the risk of renal toxicity. There is no cure.

Current biotechnology approaches to psoriasis treatment
relate to a direct pharmaceutical-mediated attack, either on

US 6,355,244 B1
3

4

cell proliferation or on the immune component of the

(3) a polynucleotide encoding an anti-idiotype for a gan
glioside. The immunological response can have humoral or

disease. Japanese patent application JP 6145069 describes

cellular components, and preferably has both.

angiogenesis inhibitors comprising ganglioside GM3 or a
GM3 analog as an active agent. At 100 pg/mL, GM3 shoWed
groWth of normal human antioendothelial cells of 4.5><104
on day 5, compared With 76><104 in controls. US. Pat. No.

Further embodiments of the invention relate to preparing
a composition for use in the treatment of psoriasis by
preparing a composition comprising the determinant in an

5,339,977 describes n-deacetyl-lysoganglioside derivatives

immunogenic form, or else raising an anti-idiotype against

for use as phospholipase A2 inhibitors for the treatment of

a monoclonal antibody that binds the antigenic determinant.
Also embodied are methods for screening a composition for

proliferative and autoimmune diseases, including various
forms of cancer, psoriasis, and rheumatoid arthritis.

10

An IL-2 fusion toxin has been developed (Seragen, Inc.)
that is designed to selectively destroy activated T cells in
psoriatic plaques, leaving normal cells alone. The objective
is to destroy activated T cells, and thereby clear the psoria
sis. APhase II study has been performed in Which test doses
of 5, 10, and 15 pig/kg Were administered per day. Compa
rable improvement Was observed in patients With moderate
to severe psoriasis. HoWever, in order to obtain this
response, the compound Was administered three days per
Week for four Weeks.

Various formulations containing the compound BCX-34
for psoriasis, cutaneous T cell lymphoma, and HIV infection
have been tested (BioWorld Today, Sep. 29, 1997; see also
WO 95/01355; WO 93/21187; WO 90/10631; US. Pat. Nos.
5,008,270, 5,008,265, and 4,985,434). BCX-34 is a small
molecule drug that inhibits purine nucleoside

composition to human subjects, and monitoring disease
progression (optionally in combination With immunological
parameters) folloWing treatment.
15

20

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a scheme for evaluating the effect of raising an

anti-GD2 immunological response using an anti-idiotype
vaccine to treat individuals With severe chronic plaque
30

NO:1) and the amino acid sequence (SEQ ID NO:2) of the
light chain variable region of 1A7 and adjoining residues.

statistically signi?cant.
35

DETAILED DESCRIPTION
40

SUMMARY OF THE INVENTION

45

resolution of the clinical features, but stabiliZation of the
condition is a satisfactory outcome. It is desirable that the
effect be enduring, so that once an effect is achieved,
readministration of the composition, if any, need occur on

50

only an occasional basis. To accomplish this, the usual mode
is to recruit active participation of the immune system of the
host to react against a target antigen on psoriatic tissue.
This invention is based in part on the discovery that
patients immuniZed systemically With a suitable vaccine
composition mount a response directed against a psoriasis

Accordingly, in one aspect, the invention provides meth
ods for treating psoriasis in an individual, comprising
administering a composition effective in stimulating a spe

comprise an antigen that shares immunological characteris
tics of an antigen that is aberrantly expressed in psoriatic

tissue (such as human psoriatic tissue). Antigens aberrantly
expressed in psoriasis include but are not limited to gan
gliosides. While a detectable immunological response is
likely to be bene?cial, efficacy can also be deduced by an
improvement in symptoms or control of the psoriatic con
dition beyond What Would be expected Without treatment.
Certain embodiments of the invention include methods
for treating psoriasis in an individual by eliciting an anti

55

60

immunogen and/or immunogenic composition, such as: (1)

Several target antigens are believed to be suitable as

a ganglioside in an immunogenic form, such as GM2, GM3,

acetyl GD3, and GT3; (2) an anti-idiotype for a ganglioside,

may be that the immune response to the target antigen
promotes elimination or metabolic doWn-regulation of cells
bearing the target antigen, or that it interferes mechanisti
cally With a pathological phenotype of affected cells (such as
antigen. As a result, the presence of the immune response
promotes the clinical resolution of the condition.

immunological response can be elicited using any suitable

such as the monoclonal antibodies 1A7, 4B5, or BEC-2; or

speci?c antigen. As illustrated in Example 3, the response
includes circulating antibodies that speci?cally adhere to
affected tissue. Without intending to be bound by theory, it

proliferation) that is mediated, at least in part, by the target

ganglioside immunological response in the subject. The

GD1b, GD2, 9-O-acetyl GD2, GD3, GD3 lactone, 9-O

It is an object of this invention to provide compositions
that are neWly applied in the treatment of psoriasis in its

various manifestations. Ideally, the compositions promote

The invention provides methods of using compositions
Which elicit an immune response against an antigen that is

ci?c immunological response against an antigen aberrantly
expressed in human psoriatic tissue. These composition(s)

FIG. 3 is a depiction of the cDNA sequence (SEQ ID

NO:3) and the amino acid sequence (SEQ ID NO:4) of the
heavy chain variable region of 1A7 and adjoining residues.

are effective When given on an occasional basis. The present
invention relates to a strategy in Which the patient’s oWn

aberrantly expressed in psoriatic tissue.

psoriasis.
FIG. 2 is a depiction of the cDNA sequence (SEQ ID

greater improvement in mean lesion scores in the treated

immune system is recruited into an active role against the
disease.

Further embodiments of the invention relate to the use of
a component selected from the group consisting of a
ganglioside, an anti-idiotype for a ganglioside, and an
expression vector encoding an anti-idiotype for a
ganglioside, in the manufacture of a medicament for the

treatment of psoriasis.

group compared to placebos, Which for these studies Was not

Accordingly, there is a need for therapeutic compositions
that are effective in managing psoriasis, particularly if they

A further embodiment of the invention is a composition
containing a ganglioside, an anti-idiotype for a ganglioside,
or a polynucleotide encoding a ganglioside, packaged With
an indication of its suitability for use in treating psoriasis.

25

phosphorylase, a human enZyme believed to be involved in

the proliferation of T cells. An oral formulation is being
tested in an ongoing Phase I/II trial. A topical formulation
advanced to the Phase III stage for both lymphoma and
psoriasis. The Phase III psoriasis study shoWed only a 14%

ef?cacy in treating psoriasis, involving administering the
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vaccine targets in psoriasis, and various types of vaccines
can be used to obtain the desired result. Illustrative examples
are given in the sections that folloW.

US 6,355,244 B1
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materials With Which it is associated in nature. Substantially
free means at least 50%, preferably at least 75%, more
preferably at least 90%, and even more preferably at least
98% free of the materials With Which it is associated in
nature, other than solvent.
A “vaccine” is a pharmaceutical composition for human

De?nitions

In reference to the therapeutic methods and compositions
of this invention, the term “psoriasis” refers to all skin
conditions in the clinical arts described by this term, and to

psoriatic-associated conditions, including psoriatic arthritis.
“Psoriatic tissue” refers to tissue affected by psoriasis and
affected cells contained Within the tissue, but not to cells that
have migrated to the site such as leukocytes. Preferably, the
psoriatic tissue is from a human.
Particular molecules referred to in this disclosure, such as

CEA, gangliosides designated GM1, GM2, and so on, are
meant to include not only the intact molecule, but also

or animal use, Which is administered With the intention of

10

conferring the recipient With a degree of speci?c immuno
logical reactivity against a particular target, or group of
targets. The immunological reactivity may be desired for

response against a psoriasis antigen.
“Immunological activity” of a particular immunogen or

experimental purposes, for treatment of a particular
condition, for the elimination of a particular substance, or
for prophylaxis. An active vaccine is a vaccine intended to
elicit an immune response in the recipient that persists in the
absence of the vaccine components.
“Adjuvant” as used herein in the context of a pharma
ceutical preparation is a chemical or biological agent given
in combination With an antibody, polynucleotide or polypep
tide to enhance its immunogenicity.
An “individual” or “subject” treated according to this
invention is a vertebrate, preferably a mammal, more pref
erably a human. Mammals include, but are not limited to,

vaccine component refers to the ability to raise an immune

farm animals, sport animals, rodents, primates, and pets.

allotypic and synthetic variants, synthetic analogs, fusion
molecules, conjugates, and other derivatives that contain the
parent molecule and its fragments that are recogniZed by
antibodies speci?c for the intact molecule.

15

An “effective amount” is an amount suf?cient to effect a
bene?cial or desired clinical result. An effective amount can
be administered in one or more doses. For purposes of this

invention, an effective amount of ganglioside, antibody, or
other composition is an amount that induces an immune

response. A speci?c immune response may comprise
antibody, B cells, T cells, and any combination thereof, and

Other terms used in this disclosure are explained Where
25

effector functions resulting therefrom. Included are the

antibody-mediated functions ADCC and complement

they arise.
General Techniques

mediated cytolysis (CMC). A T cell response can include T

The practice of the present invention Will employ, unless
otherWise indicated, conventional techniques of molecular

helper cell function, cytotoxic T cell function, or

biology (including recombinant techniques), microbiology,

in?ammation/inducer T cell function. A compound or com

cell biology, biochemistry and immunology, Which are

position able to elicit a speci?c immune response according

Within the skill of the art. Such techniques are explained

to any of these criteria is referred to as “immunogenic”.

fully in the literature, such as, “Molecular Cloning: A

An antigen that “shares immunological characteristics”
With another antigen is an antigen that, When administered
in appropriate form (such as, for example, alone, in con
junction With an adjuvant, in association With (or conjugated
to) a compound), elicits an immunological activity. For

Laboratory Manual”, second edition (Sambrook et al.,

1989); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984);
35

eds.); “Gene Transfer Vectors for Mammalian Cells” (J. M.
Miller & M. P. Calos, eds., 1987); “Current Protocols in
Molecular Biology”
M. Ausubel et al., eds., 1987);

purposes of this invention, it is also understood that an

antigen comprises an antigenic determinant(s) (as is Well
understood in the art).
A “polynucleotide” is a polymeric form of nucleotides of

“PCR: The Polymerase Chain Reaction”, (Mullis et al., eds.,
1994); “Current Protocols in Immunology” (J. E. Coligan et

any length, Which contain deoxyribonucleotides,
ribonucleotides, and nucleotide analogs in any combination.

al., eds., 1991).
All patents, patent applications, articles and publications

A“vector” refers to a recombinant DNA or RNA plasmid or

virus that comprises a heterologous polynucleotide to be

“Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods
in EnZymology” (Academic Press, Inc.); “Handbook of
Experimental Immunology” (D. M. Weir & C. C. BlackWell,

The terms “polypeptide”, “peptide” and “protein” are
used interchangeably to refer to polymers of amino acids of

mentioned herein, both supra and infra, are hereby incorpo
rated herein by reference.
Target Antigens in Psoriatic Tissue
The target antigen against Which a speci?c immune

any length, and may be interrupted by non-amino acids.
An “aberrantly expressed antigen” is an antigen that is

minant Which is aberrantly expressed in psoriatic tissue. This
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delivered into a target cell, either in vitro or in vivo.

response is desired contains an epitope or antigenic deter

uniquely expressed, overexpressed, and/or underexpressed

means that it is present in cells of the affected tissue (or the
surrounding milieu) in a manner that makes it accessible to
the immune system at a level that is signi?cantly different

in conjunction With a disease state. For purposes of this

invention, the disease state is psoriasis.

than in cells of the same tissue type that are not affected. The

An “immunogenic form” of an antigen is a form of or

formulation comprising the antigen Which renders the anti
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gen immunogenic. Such forms include, but are not limited
to, antigen alone, antigen in conjunction With one or more
adjuvants, antigen in association With or conjugated to a
moiety, such as a hapten.
A “host cell” denotes a eukaryotic cell that has been

cells in Which the epitope is aberrantly expressed Will be
resident cells of the affected area, particularly keratinocytes
or living epithelial cells, rather than migrant cells. For
purposes of this invention, compositions described herein
may comprise an antigen or an antigenic determinant.

The aberrantly expressed antigenic determinant of interest

genetically altered, or is capable of being genetically altered

can be of any chemical nature, including but not limited to

by administration of an exogenous polynucleotide, such as
a recombinant plasmid or vector. When referring to geneti

protein epitopes, carbohydrate epitopes, and glycolipids

cally altered cells, the term refers both to the originally
altered cell, and to its progeny.
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such as gangliosides. Typically, the epitope is uniquely
expressed and/or overexpressed in psoriatic tissue in a
variety of different individuals, although variations in

An “isolated” polynucleotide, polypeptide, ganglioside,

expression level may occur. Typically, the determinant Will

or other component, is one that is substantially free of the

be expressed at the cell surface or present as an insoluble but

US 6,355,244 B1
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Glycolipids suitable as target antigens include any of the

accessible antigenic mass, rather than being a soluble factor.
Histocompatibility Class I or Class II antigens are excluded

monosialyl, disialyl and trisialyl gangliosides that occur

by de?nition.

naturally on cells in psoriatic tissue. Preferred target anti
gens are GM1, GD1a, GT1, GT2, and especially GM2,

Antigenic determinants that are aberrantly expressed can
be identi?ed by a number of techniques known in the art.

GM3, N-glycolyl GM3, GD1b, 9-O-acetyl GD2, GD3, GD3

One method is to look for a particular messenger RNA
transcript that is present in an unusual abundance in affected

cells. Where the determinant is a protein antigen synthesiZed
by the cell, a suitable proxy is, for example, mRNA encod
ing the antigen. Where the determinant is a carbohydrate or
glycolipid, a suitable proxy is, for example, mRNA encod
ing an enZyme involved in forming a critical antigen-speci?c

lactone, 9-O-acetyl GD3, and GT3.
Types of Therapeutic Compositions used in this Invention
Once a suitable target antigen is identi?ed, a composition
is designed With a vieW to recruiting a speci?c immune
10

response in the subject to be treated against the aberrantly

expressed determinant. Any type of composition capable of

linkage in the synthetic pathWay.

eliciting the desired speci?c immune response is suitable.

Methods for determining mRNA that is in an unusual
abundance in one cell than another involves preparing
mRNA from both cells, and then comparing the amount of

sition comprising the target antigen, or a modi?ed version,

In some embodiments, the invention employs a compo
15

each particular mRNA betWeen the preparations. A number

amount is an amount suf?cient to elicit the desired immune

of techniques for the comparison step are related in some
Way to subtractive hybridiZation. One example involves

response. Accordingly, the antigen is administered in a
composition such that an immune response is elicited. For

producing positive and negative cDNA, respectively, from
the ?rst and second RNA preparations, and looking for
cDNA Which is not completely hybridiZed by the opposing
preparation. Subtractive hybridiZation is described in the
standard molecular biology reference books listed earlier.
Another Way of comparing production of particular mes
senger RNA is by differential display. This has been exten

20

example, the target antigen can be provided by obtaining an
enriched fraction from a suitable tissue source or cell line,

such as keratinocytes, using one of the assays described
earlier to folloW the desired activity. An illustration of this
is a vaccine for the Tn and sialylated Tn antigens, Which can
25

sively described by Liang et al. (1992, 1995), and has since
been elaborated in a number of different Ways. In this

technique, cDNA is prepared from only a subpopulation of
each RNA preparation, and expanded via the polymerase
chain reaction using primers of particular speci?city. Similar

in an immunogenic form. In other embodiments, an effective
amount of a composition is employed, Wherein an effective

be prepared from ovine submaxillary gland mucin (O’Boyle
et al.).
More typically, the target antigen is provided in synthetic
form. Where the target antigen is not previously knoWn, it is
?rst characteriZed by isolation of the antigen complex, or an

30

subpopulations are compared across several RNA prepara

mRNA encoding it. Protein antigens can then be prepared by
standard peptide synthesis, or by expressing a polynucle

tions for expression differences by gel autoradiography. In

otide encoding it in a suitable host cell. Carbohydrate and

order to survey the RNA preparations entirely, the assay can
be repeated With a comprehensive set of PCR primers. The

other non-protein antigens are generally prepared by chemi

screening strategy more effectively includes multiple posi
tive and negative control samples (Sunday et al.). By excis
ing the corresponding region of the separating gel, it is

35

(CEA antigen), and in US. Pat. No. 5,141,742 (melanoma

associated antigen p97).

possible to recover and sequence the cDNA.

Antigenic determinants that are aberrantly expressed in
psoriatic tissue can also be identi?ed directly using antibod

cal synthesis, or by a combination of synthetic and isolation
techniques. For example, use of cancer antigens as vaccine
preparations is described in BE 1008391 and W0 92/ 19266

40

Also suitable for use in immunogenic compositions to
raise an anti-ganglioside response are any monosialyl, disia

lyl and trisialyl gangliosides, along With synthetic
derivatives, including 9-O-acetyl derivatives, lactone and

ies directed against them. Psoriatic tissue or an antigen
extract can be used to screen an immunoglobulin library.

More conveniently, if the practitioner suspects a particular

lactam derivatives and analogs, and episialo derivatives;

antigen of being aberrantly expressed in psoriatic tissue, an

many of Which are referred to elseWhere in this disclosure.

antibody speci?c to the antigen can be provided and used to
test psoriatic tissue. Con?rmation of the overexpression can
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be obtained, for example, by performing a standard immu

originally designed for cancer treatment or other modes of
clinical care. For example, Helling et al. and Livingston et

noassay on solubiliZed tissue extract of affected tissue, and
comparing With a similar extract of unaffected tissue. More

preferable are immunohistology techniques, using the anti
body speci?c for the suspected target as the primary anti
body. Asuitable aberrantly expressed determinant Will result

al. describe ganglioside GD3, in the form of synthetic
50

multiple antigenic peptides, as conjugates With albumin,
KLH, or membrane proteins of Neiseeria meningitidis, or as

proteosomes. A vaccine for stimulating or enhancing pro
duction of antibodies against 9-O-acetyl GD3 is outlined in

in different staining in a section from affected tissue than

unaffected tissue, and Will also shoW speci?city for particu
lar cells in the affected sample. An illustration of this is

Included in the practice of the invention is the application
to psoriasis of ganglioside vaccines and other formulations

US. Pat. No. 5,102,663. European patent application EP
55

0443518 outlines a cancer vaccine containing episialo com

plex carbohydrates, particularly epiGM3, epiGM4, or

provided in Example 1.
Possible candidate antigens include any naturally occur

epiGM5. European patent application EP 0661061 outlines

ring ganglioside antigens, antigens that are aberrantly

vaccine compositions for eliciting an immune response

expressed in a spectrum of different cancers, such as CEA,

alpha-fetoprotein and gp-72, and antigens that are aberrantly

60

expressed in cancers of the skin, especially but not limited
to melanoma. Melanoma-associated antigens include the

that are proposed for use in a vaccine for cancer treatment.

Cheresh et al. describe the biosynthesis and expression of
the disialoganglioside GD2, a relevant target antigen on

gangliosides GM2, GD2, GD3, and their derivatives and
analogs; HMW-MAA, MPG, and gp-75. Also of interest are

the Thomsen-Friedenreich (T) antigen (Gal[31-3GalNAcot
O-Ser), Tn, and sialylated Tn (NeW5Acot2-6GalNAcot-O
Ser). Also of interest is the cell surface marker CDW60.

against N-glycosylated gangliosides for cancer treatment,
particularly N-glycolyl GM3. PCT patent application WO
93/10134 outlines ganglioside lactam analogue derivatives
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small cell lung carcinoma for monoclonal antibody
mediated cytolysis. PCT patent application WO 94/16731
outlines ganglioside-KLH conjugate vaccines With the adju

US 6,355,244 B1
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antibody recogniZing isotypic or allotypic determinants of

vant QS-21, using a ganglioside selected from GM2, GM3,
GD2, GD3, GD3 lactone, O-acetyl GD3, and GT3. The

the Ab1; (3) Positive selection for an ability to inhibit the

metabolism of these gangliosides is altered in cancers of

binding of Ab1 to the target antigen; and (4) Positive

neuroectodermal origin, including melanoma (Hamilton et

selection for an ability to induce a humoral immune

al.). Progenics Pharmaceuticals Inc. is testing a GM2-KLH
conjugate With the adjuvant QS-21 in a Phase III clinical
trial of patients With melanoma under the product name
GMK. Also being tested is a second ganglioside conjugate
vaccine, MGV, comprising a combination of KLH
conjugated GD2 and GM2. The vaccine is proposed for
therapy not only of melanoma, but also of colorectal cancer,
lymphoma, small cell lung cancer, sarcoma, gastric cancer,

response against the target antigen in experimental animals.
Typically, the ?rst step involves multiple immuniZation of an

animal With the Ab1, preparation and cloning of hybridoma
cells from the immune animal, and then testing of the cells
for the desired speci?city on a clone-by-clone basis.
10

HoWever, other Ways of raising or selecting antibody or
antibody equivalents are also suitable. Immunocompetent
phage can be constructed to express immunoglobulin vari
able region segments on their surface. See Marks et al., NeW

15

tions WO 94/13804, WO 92/01047, and WO 90/02809; and
McGuinness et al., Nature Biotechnol. 14:1149, 1996. Phage
of the desired speci?city can be selected, for example, by

and neuroblastoma (Progenics Prospectus). Any of these
compositions or their active components may be adapted for
psoriasis treatment in accordance With this invention.
Another illustration of a composition suitable for eliciting
a speci?c immunological response against a target antigen in
psoriasis is an anti-idiotype moiety. This approach to immu
niZation arises from the netWork theory of Jerne, involving
a second antibody (Ab2) raised against a ?rst antibody
(Ab1) Which in turn is speci?c for the target. The Ab2 is
selected not only for its ability to bind Ab1 speci?cally, but
also for its ability to stimulate a further antibody (Ab3) that
cross-reacts With the target. The use of anti-idiotypes in
cancer treatment is described generally in US. Pat. No.

Engl. J. Med. 335:730, 1996; International patent applica

adherence to Ab1 attached to a solid phase, and then

ampli?ed in E. coli. A further elaboration of the screening
20

25

WO 96/22373.
Of particular interest are the monoclonal antibodies (and
derivatives With the same immunogenic properties) With the
designations 1A7, 4B5, and BEC-2. The 1A7 antibody is an

30

anti-idiotype for ganglioside GD2, and is described in US.
Pat. No. 5,612,030 and International Patent Application WO
96/22373. It Was deposited With the American Type Culture
Collection (ATCC), noW located at 10801 University Blvd.,
Manassas Va. 20110-2209, USA, on Dec. 28, 1994 under

5,053,224.
The term “anti-idiotype” or “anti-idiotype moiety” as
used throughout this application is de?ned to include not

only intact antibody molecules, but any molecules compris
ing at least one variable region or portion of a variable

region With the desired functional properties. The variable
region Will typically comprise a VH—VL pair, but may
alternatively be made up of other combinations of variable

Accession No. HB-11786. The 4B5 antibody is an anti

idiotype for ganglioside GD2, and is described in US. Pat.
No. 5,653,977. The BEC-2 antibody is an anti-idiotype for
ganglioside GD3, and is described in US. Pat. No. 5,529,

chains from antibodies or T cell receptors. Variable region

fragments, fusion molecules, chimeras, and humaniZed vari

method and its use in preparing an anti-idiotype for a

ganglioside is provided in International Patent Application

35

922. Also of interest are the anti-GD2 anti-idiotypes of

ants are included, so long as the requisite functional prop

Cheung et al., and the anti-GM3 anti-idiotypes of Yamamoto

erties are retained. The variable region may be presented in
any suitable form, including but not limited to intact anti

et al., one of Which Was recombined by Hastings et al. as a

body molecules, antibody fragments (such as Fab, F(ab‘)2,
and Fv), multiple antigen proteins, and various antigen

chimera With human ogle K constant region sequences.

Preferably, anti-idiotype antibody 1A7 (for a functional
40

portion thereof, as described beloW) is used. 1A7 Was raised

binding constructs. Examples of constructs of particular

against the anti-GD2 monoclonal antibody designated

interest include fusion constructs, such as single chain

14G2a.

variable region polypeptides (scFv), in Which a single

The 1A7 antibody can be prepared in several Ways. It is

VH—VL pair are linked through a ?exible peptide linker

most conveniently obtained from the hybridoma deposited

sequence in a manner that permits the polypeptide to fold
into the three-dimensional conformation of a single variable
region. Also included are diabodies, in Which tWo variable

45

With the ATCC under Accession No. HB-11786, or the
progeny thereof. For example, the cells can be cultured in a
suitable medium, and spent medium can be used as an
antibody source. Optionally, matrix-coated channels or
beads and cell co-cultures may be included to enhance

50

groWth of antibody-producing cells. For the production of

regions are linked by a shorter linker that prevents folding
into a single variable region, but permits chains to dimeriZe
into bivalent molecules With tWo VH—VL sites. Other con
structs of interest include polymeric forms, Which contain a

plurality (i.e., more than one) polypeptide. Polymeric forms

large amounts of antibody, it is generally more convenient to
obtain an ascites ?uid. The method of raising ascites gen

may be linear or branched.

erally comprises injecting hybridoma cells into an immu

The desirable characteristics of an anti-idiotype moiety
are an ability to bind an antibody speci?c for the target
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primed for ascites production by prior administration of a
suitable composition; for example, Pristane.

antigen (Ab1), and the ability to elicit an antibody speci?c
for the target antigen When injected into the intended sub

Alternatively, 1A7 can be chemically synthesiZed in con

ject. As used herein, reference to an anti-idiotype for a

particular antigen (for example, an anti-idiotype for a
ganglioside) means an anti-idiotype that elicits an active

60

immune response speci?c for the particular antigen in an
individual When administered in an immunogenic form.
To obtain an anti-idiotype With the features desired, a

for antibody (or at least a molecule having a variable region)

capable of binding to the Ab1; (2) Negative selection against

junction With standard methods of protein synthesis. A
suitable method is the solid-phase Merri?eld technique.
Automated peptide synthesiZers are commercially available,
such as those manufactured by Applied Biosystems, Inc.

(Foster City, Calif.).

screening process is employed. A preferred screening
method involves the folloWing steps: (1) Positive selection

nologically naive histocompatible or immunotolerant
mammal, especially a mouse. The mammal is optionally
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1A7 may also be obtained by employing routine recom
binant methods such as described in Sambrook et al. (1989).

For instance, using the sequences and information provided
herein, a polynucleotide encoding either the 1A7 heavy or

US 6,355,244 B1
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light chain can be cloned into a suitable expression vector

(Which contains control sequences for transcription, such as
a promoter). The expression vector is in turn introduced into

80% pure, and free of pyrogens and other contaminants.
Methods of protein puri?cation are knoWn in the art and are
not described in detail herein. Alternatively, if a 1A7

a host cell. The host cell is groWn under suitable conditions

polypeptide(s) is expressed in a suitable storage medium,

such that the polynucleotide is transcribed and translated
into a protein. Heavy and light chains of 1A7 may be

such as a plant seed, the 1A7 polypeptide need not be
puri?ed and could even be administered Without puri?ca
tion. Fiedler et al. (1995) Biotechnology 13:1090—1093.
1A7 polypeptides can be obtained from intact 1A7, Which

produced separately, and then combined by disul?de bond
rearrangement. Alternatively, vectors With separate poly

can in turn be isolated from the hybridomaATCC Accession

nucleotides encoding each chain of 1A7, or a vector With a

single polynucleotide encoding both chains as separate

10

transcripts, may be transfected into a single host cell Which
may then produce and assemble the entire molecule.
Preferably, the host cell is a higher eukaryotic cell that can

Application WO 96/22373. Techniques of isolating antibod

provide the normal carbohydrate complement of the mol
ecule. The 1A7 thus produced in the host cell can be puri?ed

No. HB-11786 producing 1A7, Which is described in
co-oWned U.S. Pat. No. 5,612,030 and International Patent

15

ies from hybridomas are Well knoWn in the art. See, e.g.,
HarloW and Lane (1988). Once intact 1A7 is obtained, 1A7
polypeptides can be obtained by degradation of intact 1A7,

by using, for example, proteolytic enZymes (proteinases).

using standard techniques in the art. A polynucleotide
encoding 1A7 for use in the production of 1A7 by any of
these methods can in turn be obtained from the hybridoma

Examples of proteolytic enZymes include, but are not lim
ited to, trypsin, plasmin, and thrombin. Intact 1A7 can be

producing 1A7, or be produced synthetically or recombi
nantly from the DNA sequence provided herein.

can be performed sequentially. The nature and extent of the

incubated With one or more proteinases, or the digestions

proteolytic cleavage Will depend upon the desired polypep

Methods of antibody isolation are Well knoWn in the art.

See, for example, HarloW and Lane (1988) Antibodies: A

Laboratory Manual, Cold Spring Harbor Laboratory, NeW
York. The 1A7 antibody is a mouse immunoglobulin of the

IgG1 subclass, and may be isolated by any technique suit
able for immunoglobulins of this isotype. Puri?cation meth
ods may include salt precipitation (for example, With ammo

25

tide length as Well as the enZymes used. These techniques
are Well knoWn in the art. Alternatively, or in addition, intact
1A7 can be treated With disul?de reducing agents to disas
sociate the molecule.

1A7 polypeptides can also be made by chemical synthesis
using techniques knoWn in the art. 1A7 polypeptides can

nium sulfate), ion exchange chromatography (for example,

also be made by expression systems, using recombinant
methods. The availability of 1A7 polynucleotides encoding
1A7 polypeptides permits the construction of expression
vectors encoding intact 1A7, functionally equivalent frag

on a cationic or anionic exchange column run at neutral pH

and eluted With step gradients of increasing ionic strength),

gel ?ltration chromatography (including gel ?ltration
HPLC), and chromatography on affinity resins such as

ments thereof, or recombinant forms of 1A7. A polynucle

protein A, protein G, hydroxyapatite, and anti

otide encoding the desired 1A7 polypeptide, Whether in

immunoglobulin. 1A7 may also be puri?ed on affinity
columns comprising the 14G2a paratope; for example, in the

fused or mature form, and Whether or not containing a signal
35

form of a puri?ed Ab1 or Ab3. Preferably, 1A7 is puri?ed

from BALB/c ascites using Protein-A-CL-SEPHAROSETM
4B chromatography folloWed by chromatography on a
DEAE-SEPHAROSETM 4B ion exchange column.

Alternatively, an active portion (see above under descrip
tion of “anti-idiotype” or “anti-idiotype moiety”) of 1A7
may be used, Which comprise a portion of or an entire

variable region of 1A7. Examples of variable region
(Whether intact or fragments) constructs have been provided
above. FIGS. 2 and 3 provide the polypeptide sequences of
the light and heavy chain variable regions as Well as the
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polynucleotide sequences encoding the variable regions.
Preparation of these 1A7 polypeptides employs standard

sequence to permit secretion, may be ligated into expression
vectors suitable for any convenient host. Both eukaryotic
and prokaryotic host systems can be used. The polypeptide
is then isolated from lysed cells or from the culture medium
and puri?ed to the extent needed for its intended use.
Puri?cation or isolation of the polypeptides expressed in
host systems can be accomplished by any method knoWn in
the art. For example, cDNA encoding intact 1A7 or a
fragment thereof can be operatively linked to a suitable
promoter, inserted into an expression vector, and transfected
into a suitable host cell. The host cell is then cultured under
conditions that alloW transcription and translation to occur,

and the desired polypeptide is recovered. Other controlling
transcription or translation segments, such as signal
sequences that direct the polypeptide to a speci?c cell

techniques, such as recombinant techniques, in the art.
1A7 polypeptides can be produced by proteolytic or other

compartment (i.e., for secretion), can also be used. Examples

degradation of 1A7, by recombinant methods (i.e., single or

of prokaryotic host cells are knoWn in the art and include, for

fusion polypeptides) as described above or by chemical

example, E. coli. Examples of eukaryotic host cells are
knoWn in the art and include yeast, avian, insect, plant, and

synthesis. 1A7 polypeptides, especially shorter polypeptides
up to about 50 amino acids, are conveniently made by
chemical synthesis. Methods of chemical synthesis are
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animal cells such as COS7, HeLa, CH0 and other mamma
lian cells.

knoWn in the art and are commercially available. For

For scFv fragments, light and/or heavy chain variable

example, a 1A7 polypeptide could be produced by an

regions are linked using a short linking peptide. Bird et al.
(1998) Science 242:423—426. An example of a linking

automated polypeptide synthesiZer employing the solid
phase method.

peptide is (GGGGS)3(SEQ ID N015), Which bridges

Preferably, the polypeptides are at least partially puri?ed
from other cellular constituents. Preferably, the polypeptides
are at least 50% pure. In this context, purity is calculated as

a Weight percent of the total protein content of the prepa
ration. More preferably, the proteins are 50—75% pure. More
highly puri?ed polypeptides may also be obtained and are
encompassed by the present invention. For clinical use, the

polypeptides are preferably highly puri?ed, at least about

65

approximately 3.5 nm betWeen the carboxy terminus of one
variable region and the amino terminus of the other variable
region. Linkers of other sequences have been designed and
used. Bird et al. (1988). Usually the linkers are selected to
have little to no immunogenicity. For asymmetrical linkers,
the scFvs can be assembled in any order. Generally, the
entire variable regions are included in the scFv, Which may

be produced either recombinantly or synthetically.

US 6,355,244 B1
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Another illustration of a composition suitable for eliciting
a speci?c immunological response against a target antigen in
psoriasis is an expression vector encoding a polypeptide
Which is used in an immunogenic composition. The
polypeptide encoded by the vector is either one comprising

of MHC Class I cytotoxic T lymphocytes to subunit antigen
vaccines, as Well as antigen-speci?c cellular proliferation.
Preclinical trials con?rm its safety and ef?cacy at 100

pig/dose. QS-21 is supplied by Aquila Biopharmaceutical,
Inc. in Worchester, Mass.
The composition can optionally also contain other active

the antigenic determinant that is aberrantly expressed in
psoriatic tissue, or else an anti-idiotype for the aberrantly
expressed determinant. The encoding region is linked in the
vector to suitable transcription and translation control ele
ments that permit the encoding region to be expressed in the
intended subject upon administration.
Vaccines made up of naked polynucleotides are generally
described in Tang et al. (1992) Nature 356: 152—154. Viral
vectors are also suitable, including by Way of example,
vectors based on herpes viruses, hepadna viruses, Sindbis

medicinal agents, and/or non-active ingredients such
carriers, and auxiliary substances such as Wetting or emul

si?ng agents, and pH buffering agents. Additives of particu
10

lar interest are adjuncts that enhance the immunogenic
effect, such as mitogens or stimulatory cytokines. Of par
ticular interest as adjunctive agents for anti-idiotype com

positions are interleukins, particularly IL-2. The composi
tion is typically formulated in liquid form, but can also be

freeZe-dried for reconstitution by hydration.
15

associated virus. Where the encoding region encodes an

The route of administration is selected according to the
formulation of composition and the intended effect. In the
more usual embodiments of this invention, the composition

anti-idiotype, of particular interest are vectors based on
vaccinia virus that can be used in vaccine preparations

response in the subject. With this in vieW, possible routes of

virus, pseudotype retroviral vectors, adenovirus, adeno

(Moss (1991) Science 252: 1662—1667). Such vectors can be

is formulated and administered so as to stimulate a systemic
20

constructed, for example, by homologous recombination of
vaccinia plasmids and Wild-type WR strain of vaccinia virus
using CV-1 cells, according to the procedure of Mackett et
al. (DNA Cloning, Vol. II, D. M. Glover, ed., IRL Press

1985).

administration include intracutaneous, subcutaneous,

intramuscular, intraperitoneal, intradermal, oral, intranasal,
intradermal, and intrapulmonary (i.e., by aerosol). Protein
vaccines of this invention for human use are typically
25

administered by a parenteral route, most preferably subcu
taneous. Aseries of injections is preferably given at different

Formulation of Therapeutic Compositions

subcutaneous sites.

The preparation of pharmaceutical compositions is con
ducted in accordance With generally accepted procedures for

In other embodiments, the composition is formulated and
administered to produce a local effect (i.e., is formulated for

the preparation of pharmaceutical preparations. See, for
example, Remington’s Pharmaceutical Sciences 18th Ea'i
tion (1990), E. W. Martin ed., Mack Publishing Co., Pa.

topical administration). These compositions are generally
30

used to boost at an affected site a response in an individual

Where a systemic immunological response against the target

Depending on the intended use and mode of administration,

antigen has already successfully been induced, although

processing optionally includes sterilizing, mixing With

pre-generation of a systemic immune response is not
required. In these embodiments, the composition is gener

appropriate non-toxic and non-interfering components,
dividing into dose units, or enclosing in a delivery device.
Protein vaccines used in this invention typically comprise

35

an adjuvant, Which may be the same as or in addition to the

excipient or carrier. Examples of adjuvants include but are

not limited to aluminum hydroxide, alum, QS-21 (US. Pat.
No. 5,057,540), DHEA (US. Pat. Nos. 5,407,684 and 5,077,
284) including its precursors and modi?ed forms (e.g.,
DHEA-S, the sulfonated form of DHEA), [32 microglobulin

40

(US. Pat. No. 5,171,568), monophosphoryl lipid A (US.
45

as various forms and generations of DETOXTM and BCG

(US. Pat. No. 4,726,947). Other suitable adjuvants are

aluminum salts, squalene mixtures (SAP-1), muramyl
peptide, saponin derivatives, mycobacterium Wall
preparations, mycolic acid derivatives, nonionic block
copolymer surfactants, Quil A, cholera toxin B subunit,
polyphosphaZene and derivatives, and immunostimulating

50

complexes (ISCOMs) such as those described by Takahashi
55

Preferably, compositions useful for treating psoriasis
Written instructions as part of the packaging or in a product
insert. The Written instructions can simply indicate that
60

RIBITMPC. The QS-21 molecule consists of a triterpene
glycoside With the general structure of a quillaic acid
3,28-O-bis glycoside. There are tWo structural isomers des
ignated V-1 and 2-1 at a typical ratio of ~2:1, both of Which

have adjuvant activity. QS-21 has been shoWn to stimulate

a response against T-dependent antigens and unconjugated
T-independent antigens. QS-21 also augments the induction

eliciting of an immunological response against an antigen
that is aberrantly expressed in either condition.

according to the present invention are accompanied by

hydroxide and incubated to about 48° C. for about 30 min.

Especially preferred adjuvants include QS-21 and

anti-idioptype antibodies, for any of the gangliosides
described herein), and the expression vectors described
herein. Preferably, a topical formulation comprises 1A7.
Examples of suitable topical formulations, Which are Well
knoWn in the art, include ointments, creams, and gels.
In certain embodiments of the invention, the composition
is specially designed for psoriasis, comprising a formulation
and dose that is designed especially to maximiZe manage
ment of the psoriatic condition. In other embodiments, the
composition is formulated in a similar fashion as it Would be
for use in another type of therapy, such as for cancer
treatment, that shares a common objective, such as the

et al. (1990) Nature 344:873—875. For veterinary use and for

production of antibodies in animals, complete and incom
plete Freund’s adjuvant can be used. A preferred vaccine
composition for peptides and anti-idiotypes or peptide
derivatives thereof is prepared by mixing With aluminum

topical formulations of any of the target antigen (antigenic
determinants) described herein, such as gangliosides, anti

idiotype moieties (i.e., anti-idiotype moieties, including

(WO 91/16924), muramyl dipeptides, muramyl tripeptides
Pat. No. 4,436,728; WO 92/16231) and its derivatives, such

ally in the form of a cream or gel, or other combination of

the active ingredient and a readily absorbable or evaporable
excipient. The composition is then administered on the skin
at the affected site. Accordingly, the invention provides

psoriasis (in any one of its many forms) is a suitable
indication for the use of the composition. Optimally, the
instructions Will also indicate suitable subjects and
conditions, the recommended route of administration,

timing, and dosage, contraindications, potential side effects,
65

and expected bene?t.
The invention accordingly provides a composition for use
(or use of any of the compositions described herein) in the

US 6,355,244 B1
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Presence of antibody activity (for example, against a

preparation of a medicament for use in the treatment of

psoriasis. These compositions comprise any of the embodi

particular ganglioside or a particular anti-idiotype) can be
determined by standard immunoassay of serum or plasma

ments described herein. In one embodiment, the invention
provides use of a component selected from the group

samples from the treated subject. For anti-idiotype activity,
the sample is preincubated With autologous immunoglobulin

consisting of i) a ganglioside; ii) an anti-idiotype moiety for
a ganglioside; and iii) an expression vector encoding an
anti-idiotype for a ganglioside in the manufacture of a
medicament for the treatment of psoriasis. The psoriasis to

or adsorbed on a suitable af?nity resin to remove antibody

activity against isotypic and allotypic determinants. In one

be treated may be any of gluttate psoriasis, pustular

psoriasis, plaque-type psoriasis, psoriatic arthritis, and/or

10

pically or enZymatically labeled anti-immunoglobulin
reagent. Results are compared With those using preimmune

chronic plaque psoriasis. The ganglioside may be any of

GM2, GM3, GD1B, GD2, 9-O-acetyl GD2, GD3, GD3
lactone, 9-O-acetyle GD3, and GT3. The anti-idiotype moi

serum or serum from subjects immuniZed With an unrelated

ety may be any of 1A7, 4B5, or BEC-Z, and is preferably
1A7.

assay method, the sample is incubated in a microtiter plate
Well previously coated With the target antigen; the Well is
Washed, and then the reaction is developed With an isoto

15

Use of Therapeutic Compositions
Patients suitable for treatment according to this invention

antigen. Speci?city can also be measured by Western blot.
The antigen is separated by electrophoresis over a polyacry
lamide gel, blotted onto nitrocellulose, and then developed
With the sample. In an third example, the sample is incubated

have clinical or histological features of psoriasis, particu

With cells that do or do not express the antigen of interest,

larly gluttate psoriasis, pustular psoriasis, plaque-type

and then developed using a ?uorescently tagged anti
immunoglobulin. Staining frequency and intensity can then

psoriasis, or psoriatic arthritis. The compositions can also be
given to patients Who have no outWard signs of psoriasis, but
are at risk for developing the disease especially in its more
severe manifestations (because of a genetic predisposition,

family history or previous manifestations), although this is
less typical. Since the effectiveness of this invention is
believed to involve a host immunological response against

25

the target antigen, the therapeutic compositions are pre
dicted to be more effective When the individual is not
immunode?cient or immunocompromised due to a genetic

be measured by FACS analysis. A model cell line is one
expressing GD2 is M21/P6. In a fourth example, the sample
is overlaid onto a histological sample from a psoriatic lesion,
as may be taken from the treated subject, and then developed
With an enZyme-labeled anti- immunoglobulin. This is illus
trated in Example 3. The nature of the response in the sample
can be further characteriZed in any of these assays by
competition With an antibody With knoWn activity for the

target antigen. A model antibody for GD2 is monoclonal

abnormality, infection, or by chemical treatment.
The amount of the immunogenic substance administered

antibody 14G2a.
Complement mediated cytotoxicity (CMC) can be

at one time is selected With a vieW to clinical safety, and to

measured, if desired, using a cell line that expresses the
target antigen. The cell line is labeled With a cytosolic
marker, such as 51Cr. The assay is conducted by adding and

achieve the initial desired immunological and clinical result
Within a feW administrations. The range of effective con

centrations for protein immunogens is generally about 10 pg

35

incubating a sample suspected of containing antibody.

to 20 mg, and typically 200 pg to 10 mg, With the tendency

Complement is added in a suitable form, such as guinea pig

toWards higher values Where the immunogenic determinant
is a proportionately smaller part of the protein. The range of
effective concentrations for polynucleotide vaccines is gen
erally about 10 pg to 500 pg of nucleic acid, typically about

serum pre-adsorbed With the cell line. After a suitable

incubation period at 37° C., extent of 51Cr release is then
measured and compared With that of unopsoniZed control
cells. 51Cr labeled target cells can also be used to measure

50 to 100 pg. Since clinical ef?cacy is believed to correlate

antibody-dependent cell-mediated cytotoxicity (ADCC) in

With the extent of the speci?c immunological response
obtained, a dose that is clinically effective can in principle
be predicted by determining an immunogenic dose in an
animal model, and then scaling the dose appropriately for

the sample, by supplying human peripheral blood mono
nuclear cells (PBMC) from normal subjects as effector cells
45

measured by isolating PBMC from a blood sample of the
treated subject, collected into hepariniZed tubes, and sepa

human use. Administrations are typically conducted on a

Weekly or biWeekly basis until there is evidence of an

rated on a suitable gradient such as Ficoll-HypaqueTM. To

immunological or clinical response. Administration can then
be continued on a less frequent basis, such as biWeekly,

monthly, or bimonthly as appropriate.
Treatment according to this description can optionally be
combined With other regimens focused on clinical
symptoms, including but not limited to local treatment With
topical steroids, topical calcipotriol, or ultraviolet light; or
systemic treatment With methotrexate, etretinate or

at a ratio of effectorztarget cells of about 100:1.
A cell mediated immune response in a subject can be

measure T cell proliferation (a general indicator of T cell
activation against the antigen), the cells are incubated With
a range of concentrations of the target antigen. A non
speci?c mitogen such as PHA serves as a positive control;
incubation With an unrelated antigen serves as a negative

control. After incubation of the PBMCs for an appropriate
55

period (typically 5 days), [3H]thymidine incorporation is

cyclosporine. Parallel treatment can also be conducted With
a vieW to activating the immune system to make it more
responsive to the vaccine, such as simultaneous administra
tion of a mitogen or cytokine. In one example, IL-2 is
injected at a collateral site at a dose of about 1.5 to 15><106

measured, and the proliferating cells can be further charac

U m-2 day_1, either throughout the priming phase of vaccine
treatment, or as a pulse given a feW consecutive days on a

Clinical outcome is folloWed over the course of therapy
for a therapeutic effect and undesirable side-effects, as

biWeekly schedule, or any reasonable variation.
Clinical response is measured around about the time of

resolution of the clinical features, but stabiliZation of the

administration and on regular folloW-up. Immunological
response can also be measured, if desired, by collecting

periodic blood samples for analysis.

teriZed by How cytometry using cell type speci?c markers.
Cytotoxic T cell response can be measured after a period of

stimulation by presenting With 51Cr labeled antigen-bearing
target cells.

illustrated in Example 4. Ideally, the compositions promote
65

condition is a satisfactory outcome. Progression or regres

sion of the disease is folloWed according to the particular
clinical manifestations of the original presentation, and
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typically includes the number and size of psoriatic lesions,

EXAMPLES

and the extent of total body surface area that is involved.
Status can also be measured at the microscopic level as the

Example 1
Demonstration of Ganglioside Antigen in Psoriasis Tissue
In this experiment, histology sections from psoriasis

proportion of epidermal cell proliferation or the proportion
of cells expressing target antigen.
The selection of the target antigen (or antigenic
determinant) and the formulation of the immunogenic com
position can be adjusted by the manufacturer, and the exact
dose and timing for the administration can be adjusted by the

administering physician, Without departing from the spirit of

lesions Were screened for the presence of aberrantly

expressed antigens that Would be suitable targets for an
active vaccination strategy.
10

the invention.
The invention also provides methods for preparing a
composition for use in the treatment of psoriasis, comprising

raising an anti-idiotype antibody against a monoclonal anti
body that binds an antigenic determinant that is aberrantly

dermal layers. The sections Were ?xed onto slides and
15

speci?c binding by overlaying With 10% normal rabbit

body is capable of eliciting an immunological response in a

Screening Methods of the Invention
The invention also provides methods of screening immu
nogenic compositions for use in treatment of psoriasis in

20

subjects having psoriasis an immunogenic composition,

chromatography as required, and diluted to 50 pg/mL. The

25

and Washed. The sections Were developed using a

streptavidin-peroxidase conjugate, folloWed by substrate.
The panel of primary antibodies consisted of the folloW
30

35

40

sis.

45
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obtained from the American Type Culture Collection
(ATCC, Rockville Md.). 8019 has been subtyped as an

IgG1K, and is speci?c for carcinoembryonic antigen
(CEA). The ability of 8019 to bind CEA in ?xed tissue
Was con?rmed by immunoperoxidase staining of par
affin blocks of human colon cancer samples. 8019 also
speci?cally binds the CEA positive colon cancer cell
line LS174-T When used as the primary antibody in

FACS analysis.
Monoclonal antibody MC-10, also designated BrE-1, is

In any of these screening embodiments, the antigen that is
aberrantly expressed in psoriatic tissue may preferably be a
ganglioside, more preferably GD2.
55

The invention also provides kits comprising a) a compo

speci?c for human milk fat globule (HMFG), an anti
gen aberrantly expressed in breast cell carcinomas.
MC-10 has been subtyped as an IgGZbK. The ability of
MC-10 to bind HMFG in ?xed tissue sections Was

con?rmed by immunoperoxidase staining of paraf?n

sition packaged in a container and comprising an immuno
genic form of a component selected from the group con

The examples presented beloW are provided as a further
guide to a practitioner of ordinary skill in the art, and are not
meant to be limiting in any Way.

blocks of human melanoma tissue. 14G2a also speci?
cally binds the GD2 positive melanoma cell line M21/
P6 When used as the primary antibody in FACS analy

Monoclonal antibody 8019, produced from the hybridoma

the immunogenic composition.

sisting of: i) a ganglioside; ii) an anti-idiotype for a
ganglioside; and iii) an expression vector encoding an
anti-idiotype for a ganglioside; and b) Written instructions
for using the composition in the treatment of psoriasis.
Preferably, the component is 1A7.

Monoclonal antibody 14G2a, groWn from a hybridoma
cell line obtained from the Scripps Research Institution.
14G2a has been subtyped as an IgGZaK. 14G2a is
speci?c for the ganglioside antigen GD2, and does not
bind to gangliosides GM1, GM2, GM3, GD3, or GT1b.

con?rmed by immunoperoxidase staining of paraf?n

antigenic determinant in each subject treated in step a); and
c) correlating the progression of the psoriasis in relation to

Kits of the Invention

ing:

The ability of 14G2a to bind GD2 in ?xed tissue Was

ing the extent of an immunological response against the

the extent of the immunological response against the anti
genic determinant in each subject With the effectiveness of

section Was incubated With the primary antibody at room
temperature for about an hour, and then reWashed. The
section Was next overlaid With biotinylated rabbit anti

mouse immunoglobulin as secondary antibody, incubated,

comprising an immunogenic form of: i) an antigenic deter
minant that is aberrantly expressed in psoriatic tissue; ii) a
monoclonal anti-idiotype antibody for an antigenic determi
nant that is aberrantly expressed in psoriatic tissue; or iii) an

expression vector encoding either i) or ii); and b) determin

serum that had been heat-inactivated.
After Washing, the sections Were overlaid With one of a

panel of primary antibodies puri?ed by anion exchange

humans.
In some embodiments, the methods comprise the steps of

(a) administering to a plurality of human subjects having
psoriasis an immungenic composition comprising an immu
nogenic form of i) an antigenic determinant that is aberrantly
expressed in psoriatic tissue; ii) an monoclonal anti-idiotype
antibody for an antigenic determinant that is overexpressed
in psoriatic tissue; or iii) an expression vector encoding
either i) or ii); and (b) correlating the progression of the
psoriasis in the human subjects treated in step (a) in relation
to that ihn untreated human subjects having psoriasis, With
the effectiveness of the immunogenic composition.
In other embodiments, the screening methods comprise
the folloWing steps: a) administering to a plurality of human

deparaf?niZed by a series of graduated Washes of decreasing
ethanol content. Once equilibrated into phosphate-buffered
saline, pH 7.4, the sections Were blocked against non

expressed in psoriatic tissue, Wherein the anti-idiotype anti
human against the antigenic determinant. Alternatively, the
methods comprise preparing an immunogenic composition
comprising the aberrantly expressed determinant.

Skin-punch biopsies Were obtained from patients having
benign Psoriasiform Dermatitis. Paraf?n blocks from three
samples Were cut into 5 pm cross-sections through the

60

blocks of human breast cancer samples. MC-10 also
speci?cally binds the HMFG positive breast cancer cell
lines MCF-7 and SKBR3 When used as the primary

65

A monoclonal mouse IgG2b of unknoWn speci?city, pur
chased from Sigma Chemical Co., serving as a negative
control.
Staining intensity Was graded on a scale of (—) to (++++).
The folloWing results Were obtained:

antibody in FACS analysis.
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periodic serum samples were collected to determine the
TABLE 1

presence of human anti-mouse (HAMA) activity and anti

Immunohistochemical staining for aberrantlv expressed antigen

the course of immunization subcutaneously. All patients
seroconverted positive with respect to both HAMA and
anti-1A7, as determined by immunoassay. The response

1A7 activity. Titers were low, and it was decided to continue
Staining Intensitv

Primary Antibody

Sample 1

14G2a
8019
MC10

Sample 2

comprised speci?c Ab3 activity, as demonstrated by the

Sample 3

+++

+++

+++

++++

++++

++++

1

1

1

mouse IgG2b control

—

—

—

PBS

—

—

—

ability of each serum to inhibit the binding of radiolabeled
10

1A7 to solid-phase linked 14G2a (Ab1). None of the patients
have yet shown objective clinical responses related to their
cancer. However, three of the seven patients (270+ to 510+
days) have stable disease and continue on vaccine therapy.
The results demonstrate that administration of 1A7 as a

Both 14G2a and 8019 antibodies gave strong staining in
all samples tested. The staining pattern was consistent with

pharmaceutical composition with the adjuvant QS-21 is very
15

speci?c staining for affected tissue, since only dermal layers
were stained. Monoclonal antibody MC10 was essentially

20

To investigate the nature of the response further, anti-1A7
antibody was affinity puri?ed from the sera of four of the
patents. First, each sample was passed over a column of
14G2a antibody, eluted with a glycine buffer (pH~2.5), and
exchanged into PBS. Next, HAMA activity that was not Ab3
was depleted by negative selection on a mouse immunoglo
bulin adsorbant. The amount of speci?c anti-1A7 (Ab3)

25

per dose), yield 0.67 mg Ab3 from 10 mL serum. Patient 2

negative.
These results indicate that both GD2 and CEA are can

didate targets for a vaccine strategy against psoriasis.

Example 2
Eliciting an Anti-GD2 Response in Humans using
an Anti-idiotype

Hybridoma cells expressing monoclonal anti-idiot anti
body 1A7 (U.S. Pat. No. 5,612,030) were used for the
production of ascites ?uid. 9.7 g of puri?ed antibody was
prepared by TSD BioServices under GMP-conditions. The
regulatory testings on the antibody preparation were com

well tolerated up to a dose of 8 mg, and is highly effective
in generating an anti-GD2 response.

obtained was as follows: Patient 1 (administered 1 mg 1A7

(administered 2 mg 1A7 per dose), yield 1.32 mg Ab3 from
10 mL serum. Patient 3 (administered 4 mg 1A7 per dose),
yield 1.71 mg Ab3 from 10 mL serum. Patient 4

(administered 4 mg 1A7 per dose), yield 0.73 mg Ab3 from
30

10 mL serum. This indicates that a substantial amount of

pleted according to FDA guidelines. This example describes

Ab3 is produced as a result of administering 1A7 at any of

how the antibody is tested in a human clinical study to verify
safety and demonstrate its ability to elicit an anti-GD2

the doses tested, and apparently is in molar excess of antigen
in the circulation.
The af?nity and speci?city of the response to GD2 was

response in humans.
Patients are immunized with 1A7 antibody mixed with
100 pg of QS-21 adjuvant. Patients are randomized to one of
the four dose levels. The total number of patients is between

35

assay plate was coated with ganglioside GD2 or GD3,

about 12 and 32. Injections are given biweekly for four total
doses, or until an immune response is observed. Therapy

continues with monthly injections until tumor progression is

40

found. Patients are monitored carefully for anaphylaxis,
serum sickness, and other potential side effects.
Periodic blood samples are obtained to determine the
effect on hematopoietic cells as well as renal and hepatic

overlaid with puri?ed Ab3, and then developed with alkaline
phosphatase labeled anti-immunoglobulin. The results
showed that each patient’s response comprises the produc
tion of anti-GD2 antibody (Ab1‘)., but not anti-GD3 anti
body. In another test, an assay plate was coated with GD2,

45

function. All patients entered into the study undergo leuka
pheresis prior to the ?rst immunization (pre-therapy). In
addition, blood samples are obtained prior to each injection

overlaid with puri?ed Ab3, and then developed with isotype
speci?c anti-immunoglobulin reagents. The anti-GD2
response was apparently a mature response comprising both

IgG and IgM, with IgG predominating.
Inhibition titration experiments were conducted using
puri?ed Ab3 from three different patients. In one test, an

of 1A7 to determine serum levels of Ab3 and Ab1‘ antibod

ies and cytotoxic T cell responses. The speci?city of the
humoral responses is con?rmed by immune ?ow cytometry,

further con?rmed by using the af?nity puri?ed Ab3 in
several of the assay systems described earlier. In one test, an

50

assay plate was coated with ganglioside GD2, and varying
amounts of puri?ed Ab3 were tested for the ability to inhibit

radioimmunoassay, and dot blot analysis. Antiglobulin

the binding of radiolabeled 14G2a (Ab1). The half-titration

responses to the murine antibody is tested by sandwich

point for each Ab3 was comparable to that of unlabeled
14G2a. In another test, varying amounts of puri?ed Ab3
were tested for their ability to inhibit the binding of radio
labeled 14G2a to the GD2-expressing murine lymphoma
cell line EL4. The results indicated that the Ab3 induced by
administration of 1A7 competes for binding to GD2 aber

radioimmunoassay. Sera are also tested for an ability to

inhibit the binding of anti-GD2 mAb to GD2 antigen. The

55

immune pro?le of patients is further assessed by testing the
proliferative response of patient’s lymphocytes to anti
idiotype antibody, puri?ed GD2 antigen, and irradiated
tumor cells and the cytotoxicity of patient’s lymphocytes for
GD2-positive HLA-matched cell lines or autologous tumor

cells (where possible).

60

rantly expressed by model target cells.
Example 3
Demonstration of Antibody to Psoriasis-associated Antigen

in the Serum of Immunized Human Subjects
What follows are the results from seven participating in
Ab3 af?nity puri?ed-from the sera of human patients
the study over a suf?cient period to evaluate the presence of
treated with an anti-idiotype were tested for the presence of
an immunological response. Each patient was immunized
with 1 mg, 2 mg, 4 mg, or 8 mg of antibody 1A7 in QS-21 65 circulating antibody against a psoriasis associated antigen.
Patients were treated with monoclonal anti-idiotype 1A7
on a biweekly schedule. For the ?rst few patients in the
study, the ?rst 2 to 4 doses were given intramuscularly, and

(an anti-idiotype for GD2), or with anti-idiotype 3H1 (an

US 6,355,244 B1
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anti-idiotype for CEA). Treatment of subjects With 1A7 is

Was isolated, and found to react With a target antigen on

described in Example 2. The preparation and use of 3H1 is
described in PCT patent applications WO 96/20219 and WO
96/20277.

psoriatic tissue (Example 3).
This example provides a method for testing the ef?cacy of

After a course of multiple immunizations on a biweekly

immunization schedule, the respective Ab3 present in Were
prepared by passing immune sera over an af?nity column

made of the immunizing antibody, and recovering the bound
fraction. As a negative control, normal or preimmune human
IgG Was prepared by passing serum of an unimmunized

10

subject over a Protein G column.

renal and hepatic function tests, granulocyte count; 1000
mm_3> platelets>100,000 mm_3, absence of allergy to mouse
protein, and ability to provide informed consent. Subjects

The puri?ed IgG fractions Were then tested for their

ability to speci?cally stain affected psoriasis tissue, using the
immunohistochemical methods described in Example 1. The
results are shoWn in the folloWing Table:

raising an anti-GD2 immunological response in the treat
ment of psoriasis.
Fifteen patients Who have been diagnosed With severe
chronic plaque psoriasis, and Who have had an unsatisfac
tory response to a prior systemic therapy, topical steroids or
ultraviolet light are treated. Eligibility criteria also include
absence of active infection or blood-born disease, adequate

are pre-screened for the presence of GD2 antigen on kera
15

tinocytes in psoriatic lesions by immunohistology, as exem

pli?ed in Example 1.
TABLE 2

FIG. 1 shoWs the scheme of treatment. The admitted
patients are treated With 2 mg of 1A7, mixed With 100 pg of

Tissue staining by antibody present in the sera of immunized patients

the adjuvant QS-21. Four injections are given initially, one
every other Week, and then injections are given monthly.

Staining Intensity

Treatment is stopped if there is a signi?cant adverse event,
if there is substantial advancement of the disease, or if there
is no signi?cant effect after six months. Patients Who shoW

Sample Sample Sample Sample
Primary Antibody

1

2

3

4

+++

+++

+++

+++

++++

++++

++++

++++

(Abl for 1A7; positive control)
Ab3 from patients treated With 1A7

advancement of the disease are folloWed for an additional
25

normal human IgG

—

—

—

—

Ab3 from patients treated With 3H1

—

—

—

—

six months after the cessation of treatment. Patients With
stable or improved disease six months after initiation of
treatment receive further treatment for an additional six

months, folloWed by another evaluation.
During the course of the trial, patients are monitored for
toxicity. Periodic blood samples are taken to determine any

The results shoW that treatment of human patients With
monoclonal antibody 1A7 successfully elicits an active
immune response that is speci?c for a target antigen on

effect on hematopoietic cells, renal and hepatic function,
LDH, and uric acid. The most likely side effects are local

affected psoriasis tissue. The target antigen is shared
betWeen different psoriasis patients, and (in vieW of the
knoWn immunogenic properties of the 1A7 antibody) most
probably is GD2. Speci?city is con?rmed by tWo additional
observations: a) the staining pattern With Ab3 from the 1A7
treated subject shoWed staining of the affected skin cells but

skin reaction, fever, chilling, and sWeating, seldom requiring
therapy and persisting for only a feW hours. Anti-pruritics
are used Where needed. Allergic reactions are treated symp

tomatically With diphenhydramine or hydroxyzine. Bron
chospasm and anaphylaxis, if they occur, are treated With
epinephrine and supportive care, and result in removal of the
patient from the treatment regimen. In vieW of previous tests
of 1A7 in cancer patients (Example 2), major toxicity is not

not surrounding muscle ?bers; b) anti-idiotype antibody
3H1 raises a speci?c Ab3 response, but the response Was

apparently not speci?c for psoriasis tissue.
Example 4
Treating Psoriasis by Eliciting an Active Anti-ganglioside

anticipated.
Periodic blood samples are also taken to folloW the

immunological response in each patient. The presence of

Immunological Response
Psoriasis afflicts approximately 1 to 2 percent of the adult

45

population in various forms. Patients With extensive plaque

immunoassay. Serum or isolated Ab3 is also tested for
binding to GD2 expressed on tumor cell lines or psoriatic

psoriasis and pustular psoriasis frequently require systemic
therapy. Topical steroids, topical calcipotriol, or ultraviolet
light may not give adequate control. The currently used

tissue. Antibody-dependent cellular cytotoxicity, T cell pro
liferative activity, or cytotoxic T cell activity may also be
measured according to the procedures described elseWhere
in this disclosure. Induction of both humoral and cellular

systemic medications such as methotrexate, etretinate and
cyclosporine are sometimes effective, but associated With

signi?cant side effects.

anti-GD2 activity is anticipated in the majority of treated

A patient With advanced psoriasis Was administered

subjects after four or more injections With the 1A7 vaccine.
Results are determined as folloWs. Symptoms are graded

monoclonal antibody 1A7 as part of a clinical trial for the

treatment of melanoma. After leaving the trial, the patient

antibodies against 1A7 (the Ab3 response) and against GD2
(the Ab1‘ response) is measured by standard plate-binding

55

returned to the attending physician (Dr. K. Foon) and
reported that his psoriatic systems, Which had previously

according to the Psoriasis Area and Severity Index. Severity
is graded on a numerical scale (0=none; 1=slight;

2=moderate; 3=severe), taking into account erythema,

been persistent, had improved. His case history and results

scaling, and induration. The extent is based on total body

of the immunological tests Were revieWed, and it Was

surface involvement (trunk=35%; legs=35%; arms=20%;

discovered that the resolution of the symptoms correlated
With the stimulation of an anti-GD2 immune response (as

head and neck=10%). Progression is then graded betWeen —1
and +3 (—1=Worse; 0=stable; +1=minimal improvement;

detected in serum) during his treatment With 1A7 in the

+2=de?nite improvement; +3=clearing). Clinical experience

melanoma trial. Subsequently, psoriasis tissue samples from
several patients Were evaluated by immunohistochemistry
(Example 1), and all Were positive for an antigen recognized
by anti-GD2 antibody. Antibody present in the serum of

is that Without treatment, the disease Will typically progress,

several patients immunized With the GD2 anti-idiotype 1A7

65

involving more surface or having plaques With more
erythema and induration. The treatment is considered to be
successful if there is substantial improvement or stabiliza

tion of the disease, compared to the typical course in patients

US 6,355,244 B1
24

23
not treated With the vaccine, and initially presenting With
similar symptoms and clinical experience.
Although the foregoing invention has been described in

noma cells to ganglioside-KLH conjugate vaccines.

Immunol. RevieW, 145:147—166, 1995.
18. Mittelman A. et al. Human high molecular Weight

some detail by Way of illustration and example for purposes
of clarity and understanding, it Will be apparent to those
skilled in the art that certain changes and mod?cations Will

melanoma-associated antigen (HMW-MAA) mimicry by
mouse anti-idiotypic monoclonal antibody MK2-23:
Induction of humoral anti-HMW-MAA immunity and
prolongation of survival in patients With stage IV mela

be practiced. Therefore, the description and examples should
not be construed as limiting the scope of the invention,

noma. Proc. Natl. Acad. Sci. USA 89:466—470, 1992.

Which is delineated by the appended claims.
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SEQUENCE LISTING

NUMBER OF SEQ ID NOS: 5

SEQ ID NO 1
LENGTH: 447
TYPE: DNA
ORGANISM: Mus Musoulus
FEATURE:
NAME/KEY: CDS
LOCATION: (1) . . (447)

NAME/KEY: matipeptide
(58) . . (447)

SEQUENCE: 1
oot

a99

otg ttg

Arg

Leu Leu

otg atg tto
Leu Met Phe

oot got
Pro Ala

48

ooa oto too otg oot gto
Pro Leu Ser Leu Pro Val

96

t99 att
Trp Ile

—10
too ago
Ser Ser

gat gat gtt ttg atg aoo oaa act
Asp Asp Val Leu Met Thr Gln Thr
—1

agt

ott 99a
Ser Leu Gly

l

10

gat oaa goo
Asp Gln Ala

15

gta
Val

too ato tot
Ser Ile Ser

tgo aga
Cys Arg

20

tot agt oag ago att
Ser Ser Gln Ser Ile

144

25

oat agt aat 99a aao aoo tat tta gaa
'
HlS
Ser Asn Gly Asn Thr Tyr Leu Glu

t99 tao
Trp Tyr

ota oag
Leu Gln

aaa

ooa

Lys

Pro

192

40

99c oag tot ooa aao oto otg ato tao ttt gtt too aao oga ttt tot
Gln Ser Pro Asn Leu Leu Ile Tyr Phe Val Ser Asn Arg Phe Ser

240

Gly

50

55

999

gto

ooa

gao (:199 tto

agt 99c agt 99a

Gly

Val Pro

Asp Arg Phe

Ser

Gly

65

999 got 999
Glu Ala Glu

80
ttt

oaa

99t

Gly

toa 999 aoa
Ser Gly Thr

toa oat gtt oog
Ser His Val Pro

gat otg 999 gtt tat tao tgo
Asp Leu Gly Val Tyr Tyr Cys

t99 aog tto 99t 999 99c aoo aag otg
Trp Thr Phe Gly Gly Gly Thr Lys Leu

aaa c99 got gat got goa
Lys Arg Ala Asp Ala Ala

too agt aag ott 999
Ser Ser Lys Leu Gly

115

288

336

90

100

1 10

gat tto aoa
Asp Phe Thr
75

85

95

gaa ato
Glu Ile

Gly

6O

70

oto aag ato ago aga
Leu Lys Ile Ser Arg

Phe Gln

Ser

384

105
ooa aot gta too ato tto ooa ooa
Pro Thr Val Ser Ile Phe Pro Pro

120

HMFG anti-idiotype
vaccines

vaccines With QS-21

ttg

GD2 anti-idiotype
vaccines

CEA vaccinia vaccine

Met Lys Leu Pro

CEA anti-idiotype
vaccines

JP 6145069

LOCATION:

CEA anti-idiotype
vaccines

432

125
447

US 6,355,244 B1
27

28
—oontinued

130

SEQ ID NO 2
LENGTH: 149
TYPE: PRT
ORGANISM: Mus Musculus

SEQUENCE:
Met

Lys

Leu Pro Val

Arg

Leu Leu Val Leu Met Phe

—15
Ser Ser

Asp Asp Val

Gly Asp

Pro Ala

—5

Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val

1
Ser Leu

Trp Ile

—10

10

Gln Ala Ser Ile Ser

Cys Arg

Ser Ser Gln Ser Ile

15

Val His Ser Asn

Gly

30

Gly

Asn Thr

Tyr

Leu Glu

35

Gln Ser Pro Asn Leu Leu Ile

Val Pro

Asp Arg Phe

Lys Ile

Phe Gln

Gly

Ser

Tyr Phe Val

Glu Ile

Ser

Gly

Ser

Gly

Ser His Val Pro

Ser

Gly

Thr

Ser

Asp Phe Thr

Leu

Gly

Val

Tyr Tyr Cys

Trp Thr Phe Gly Gly Gly Thr Lys

Leu

105

Lys Arg Ala Asp Ala Ala

Pro Thr Val Ser Ile Phe Pro Pro

115
Leu

Arg Phe
60

100

Lys

Pro

75

Arg Val Glu Ala Glu Asp

110
Ser Ser

Ser Asn

70

95

Lys

45

55

65
Leu

Leu Gln

40

50

Gly

Trp Tyr

120

125

Gly
130

SEQ ID NO 3
LENGTH: 458
TYPE: DNA
ORGANISM: Mus Musculus
FEATURE:
NAME/KEY: CDS
LOCATION: (1) . . (456)

NAME/KEY: matipeptide
LOCATION:

(5s ) . . (456)

SEQUENCE: 3

atg gct gtc ttg 999 ctg
Met Ala Val Leu

Gly

ctc ttc
Leu Leu Phe

tgc ctg
Cys Leu

aca ttc cca agc
Thr Phe Pro Ser

—10

—5

—15

gtc ctg tcc cag
Val Leu Ser Gln

cag
Gln

tca 9951 cct ttc ctg
Ser Gly Pro Phe Leu

aag

Lys

tgt
Cys

48

ccc

96

Pro

—1
ccc tca cag agc ctg tcc atc aca
Pro Ser Gln Ser Leu Ser Ile Thr

15
acc

acc

Thr Thr

20

tca 999 ttc tca tta
Ser Gly Phe Ser Leu

144

25

tat 99t gta agc t99 att cgc cag
Tyr Gly Val Ser Trp Ile Arg Gln

30

9519
Glu

tgc act gtc
Cys Thr Val

35

cct cca 9951 aag
Pro Pro Gly Lys

40

99t ctg

Gly

192

Leu

45

t99 ctg 9951 gca att t99 99t gac 999 acc aca
Trp Leu Gly Ala Ile Trp Gly Asp Gly Thr Thr

aat tat cat tca
Asn Tyr His Ser

240

aac tcc aag agc caa
Asn Ser Lys Ser Gln

288

55

gct

ctc ata tcc aga

Ala Leu Ile Ser
65

gtt

ttc tta

aaa

Val Phe Leu

Lys

Arg

ctg agc atc agc aag
Leu Ser Ile Ser Lys
70

ctg aac agt ctg caa act
Leu Asn Ser Leu Gln Thr

gat
Asp

75

gat gac acg gcc acg tac
Asp Asp Thr Ala Thr Tyr

336

